NVS
Price
$147.14
Change
+$2.14 (+1.48%)
Updated
Jan 23 closing price
Capitalization
281.18B
11 days until earnings call
Intraday BUY SELL Signals
RHHBY
Price
$55.23
Change
+$0.44 (+0.80%)
Updated
Jan 23 closing price
Capitalization
352.38B
5 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NVS vs RHHBY

Header iconNVS vs RHHBY Comparison
Open Charts NVS vs RHHBYBanner chart's image
Novartis AG
Price$147.14
Change+$2.14 (+1.48%)
Volume$1.82M
Capitalization281.18B
Roche Holding
Price$55.23
Change+$0.44 (+0.80%)
Volume$1.82M
Capitalization352.38B
NVS vs RHHBY Comparison Chart in %
NVS
Daily Signal:
Gain/Loss:
RHHBY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NVS vs. RHHBY commentary
Jan 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Hold and RHHBY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 24, 2026
Stock price -- (NVS: $147.14 vs. RHHBY: $55.23)
Brand notoriety: NVS and RHHBY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 112% vs. RHHBY: 71%
Market capitalization -- NVS: $281.18B vs. RHHBY: $352.38B
NVS [@Pharmaceuticals: Major] is valued at $281.18B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $352.38B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $952.56B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $113.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 4 FA rating(s) are green whileRHHBY’s FA Score has 2 green FA rating(s).

  • NVS’s FA Score: 4 green, 1 red.
  • RHHBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than RHHBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 2 TA indicator(s) are bullish while RHHBY’s TA Score has 3 bullish TA indicator(s).

  • NVS’s TA Score: 2 bullish, 4 bearish.
  • RHHBY’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, RHHBY is a better buy in the short-term than NVS.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +1.94% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was +1.81% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.23%. For the same industry, the average monthly price growth was +3.69%, and the average quarterly price growth was +13.08%.

Reported Earning Dates

NVS is expected to report earnings on Feb 04, 2026.

RHHBY is expected to report earnings on Jan 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+1.23% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBY($352B) has a higher market cap than NVS($281B). RHHBY has higher P/E ratio than NVS: RHHBY (29.70) vs NVS (20.13). RHHBY YTD gains are higher at: 7.097 vs. NVS (6.724). NVS has higher annual earnings (EBITDA): 22.9B vs. RHHBY (18B). RHHBY has more cash in the bank: 12B vs. NVS (9.75B). NVS (32B) and RHHBY (33B) have identical debt. RHHBY has higher revenues than NVS: RHHBY (63.5B) vs NVS (56.4B).
NVSRHHBYNVS / RHHBY
Capitalization281B352B80%
EBITDA22.9B18B127%
Gain YTD6.7247.09795%
P/E Ratio20.1329.7068%
Revenue56.4B63.5B89%
Total Cash9.75B12B81%
Total Debt32B33B97%
FUNDAMENTALS RATINGS
NVS vs RHHBY: Fundamental Ratings
NVS
RHHBY
OUTLOOK RATING
1..100
8018
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
17
Undervalued
PROFIT vs RISK RATING
1..100
948
SMR RATING
1..100
2999
PRICE GROWTH RATING
1..100
4441
P/E GROWTH RATING
1..100
3217
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (14) in the Pharmaceuticals Major industry is in the same range as RHHBY (17) in the null industry. This means that NVS’s stock grew similarly to RHHBY’s over the last 12 months.

NVS's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHBY (48) in the null industry. This means that NVS’s stock grew somewhat faster than RHHBY’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBY (99) in the null industry. This means that NVS’s stock grew significantly faster than RHHBY’s over the last 12 months.

RHHBY's Price Growth Rating (41) in the null industry is in the same range as NVS (44) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to NVS’s over the last 12 months.

RHHBY's P/E Growth Rating (17) in the null industry is in the same range as NVS (32) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSRHHBY
RSI
ODDS (%)
Bearish Trend 1 day ago
42%
Bearish Trend 1 day ago
46%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
44%
Bearish Trend 1 day ago
47%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
51%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
52%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
45%
Bullish Trend 1 day ago
53%
Advances
ODDS (%)
Bullish Trend 13 days ago
48%
Bullish Trend 1 day ago
54%
Declines
ODDS (%)
Bearish Trend 17 days ago
44%
Bearish Trend 20 days ago
46%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
42%
Bearish Trend 1 day ago
49%
Aroon
ODDS (%)
Bullish Trend 1 day ago
42%
Bullish Trend 1 day ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signal:
Gain/Loss:
RHHBY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BTCL29.650.03
+0.12%
T-Rex 2X Long Bitcoin Daily Target ETF
DEUS60.60-0.30
-0.50%
Xtrackers Russell US Multifactor ETF
BDCX24.24-0.24
-0.97%
ETRACS Qrtly Py 1.5X Lvgd Wls Fg BDC ETN
QQQJ39.00-0.42
-1.07%
Invesco NASDAQ Next Gen 100 ETF
IWM264.81-4.98
-1.85%
iShares Russell 2000 ETF

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.48%
GSK - NVS
69%
Closely correlated
+1.03%
AZN - NVS
61%
Loosely correlated
+1.37%
PFE - NVS
59%
Loosely correlated
-0.08%
AMGN - NVS
56%
Loosely correlated
-0.67%
JNJ - NVS
54%
Loosely correlated
+0.76%
More

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
+0.80%
RHHVF - RHHBY
65%
Loosely correlated
+1.70%
NVS - RHHBY
37%
Loosely correlated
+1.48%
JNJ - RHHBY
37%
Loosely correlated
+0.76%
RHHBF - RHHBY
32%
Poorly correlated
N/A
BMY - RHHBY
28%
Poorly correlated
-0.53%
More